Meet The Professor: Optimizing the Management of ER-Positive and Triple-Negative Breast Cancer — Part 2 of a 3-Part Series

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following any-grade adverse events was most commonly observed with the addition of capivasertib to fulvestrant in the Phase III CAPItello-291 trial for patients with HR-positive, HER2-negative advanced breast cancer?

   a. Anemia
   b. Diarrhea
   c. Insomnia
   d. Weight gain

2. The next-generation oral selective estrogen receptor degrader (SERD) camizestrant is currently under investigation in the Phase III SERENA-6 trial in combination with CDK4/6 inhibition for which patients with breast cancer?

   a. Those with newly diagnosed localized breast cancer
   b. Those with advanced breast cancer who experienced disease progression on prior fulvestrant or investigational SERD
   c. Those with HR-positive, HER2-positive, ESR1 wild-type advanced breast cancer
   d. Those with HR-positive, HER2-negative advanced breast cancer with ESR1 mutations

3. Which of the following proteins is targeted by datopotamab deruxtecan?

   a. CDH1
   b. CHEK2
   c. PALB2
   d. TROP2

4. The Phase III DESTINY Breast04 trial evaluating trastuzumab deruxtecan for previously treated HER2-low advanced breast cancer revealed which of the following results in terms of objective responses in HR-positive versus HR-negative disease?

   a. Patients with HR-positive disease had significantly superior outcomes
   b. Patients with HR-negative disease had significantly superior outcomes
   c. Outcomes were similar for patients with HR-positive and HR-negative disease

5. Which of the following premenopausal patients with node-negative, ER-positive, HER2-negative breast cancer appeared most likely to derive benefit from chemotherapy in the TAILORx trial?

   a. Those with a Recurrence Score® (RS) of <10
   b. Those with a RS of 11 to 15
   c. Patients with a RS of 21 to 25
   d. RS did not appear to correlate with chemotherapy benefit in this population